FAR INTL (02516) has separately entered into six pre-sale contracts with its subsidiary and Hangzhou Xingyi Real Estate.
Pan Far International (02516) announced that in June 2025, the buyer Hangzhou Pan Far International Logistics Co., Ltd. (a...
FAR INTL (02516) announced that in June 2025, the buyer Hangzhou FAR INTL Logistics Co., Ltd. (an indirect wholly-owned subsidiary of the Company) and the seller Hangzhou Xingyi Real Estate Co., Ltd. entered into six pre-sale contracts (supplemented by supplementary agreements) to acquire a property located in Hangzhou, China, for a total consideration of RMB 52,323,300.
The property is a building named Xinyue Mingzuo 2 Building (the Building), currently under construction on a piece of land in Gongshu District, Hangzhou, China. The Building has a total of 6 floors, including 5 above ground floors and 1 underground floor, suitable for commercial and office use. The Building obtained a pre-sale permit issued by the Hangzhou Housing Security and Real Estate Management Bureau in March 2025. The subject matter of the pre-sale contracts includes unit 1 at Xinyue Mingzuo 2 Building, units 201, 301, 401, and 501 at Building 2, as well as parking spaces 01-03 and 05-08 at Building 2.
Upon completion of the pre-sale contracts, the property will be used as the group's future office. Currently, the Company's headquarters at Unit 201, Hangzhou Cross-border E-commerce Industrial Park, 22 Changcheng Street, Gongshu District, Hangzhou, Zhejiang, China, is a leased property. Considering the relatively low prices in the Chinese real estate market, the Company sees this as a good opportunity for the group to acquire its own property for use as the group's office, which will effectively reduce the group's future monthly rental expenses and cash outflows in the long run.
Related Articles

ZYLOXTB (02190) spent 1.2451 million HKD on September 22 to repurchase 50,000 shares.

LEON INSPECTION (01586) spent HKD 148,200 to repurchase 52,000 shares on September 22nd.

Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) under its subsidiary Hangzhou Mipeng plans to invest 15 million yuan in a partnership enterprise to lay out strategic emerging industries such as biopharmaceuticals and hard technology.
ZYLOXTB (02190) spent 1.2451 million HKD on September 22 to repurchase 50,000 shares.

LEON INSPECTION (01586) spent HKD 148,200 to repurchase 52,000 shares on September 22nd.

Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) under its subsidiary Hangzhou Mipeng plans to invest 15 million yuan in a partnership enterprise to lay out strategic emerging industries such as biopharmaceuticals and hard technology.
